Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm

Circulating tumor DNA (ctDNA) is a new pan-cancer tumor marker with important applications for patient prognosis, monitoring progression, and assessing the success of the therapeutic response. Another important goal is an early cancer diagnosis. There is currently a debate if ctDNA can be used for e...

Descripción completa

Detalles Bibliográficos
Autores principales: Pons-Belda, Oscar D., Fernandez-Uriarte, Amaia, Diamandis, Eleftherios P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700281/
https://www.ncbi.nlm.nih.gov/pubmed/34943407
http://dx.doi.org/10.3390/diagnostics11122171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700281/
https://www.ncbi.nlm.nih.gov/pubmed/34943407
http://dx.doi.org/10.3390/diagnostics11122171

Ejemplares similares